Offering people a choice for colorectal cancer screening

Gut

Volumn 62, Issue 5, 2013, Pages 735-740

  Senore, Carlo ^a,d   Ederle, Andrea ^b   Benazzato, Luca ^b   Arrigoni, Arrigo ^a   Silvani, Marco ^a   Fantin, Alberto ^b   Fracchia, Mario ^c   Armaroli, Paola ^a   Segnan, Nereo ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Section of Vascular Surgery   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d Centro di Prevenzione Oncologica (CPO) Piemonte   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COHORT ANALYSIS; COLON ADENOMA; COLON POLYP; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; PATIENT ASSESSMENT; PATIENT PREFERENCE; PRIORITY JOURNAL; SIGMOIDOSCOPY;

COHORT STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; ITALY; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PATIENT PREFERENCE; PREVALENCE; SIGMOIDOSCOPY;

EID: 84875844899     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301013     Document Type: Article

References (32)

1. Pecorelli S, Leo E, Veronesi U. Screening Oncologici. Raccomandazioni per la pianificazione e l'esecuzione degli screening di popolazione per la prevenzione del cancro della mammella, del cancro della cervice uterina e del cancro del colon-retto. Roma: Ministero della Salute. Direzione Generale della Prevenzione, 2006.
2. Halloran S, Launoy G, Zappa M. Feacl occult blood testing. Charter 4 pages 103-44. In: von Karsa L, Patnick J, Segnan N, eds. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. 1st edn. Luxembourg: IARC-WHO. European commission. Publication office of the European Union, 2010.
3. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210-14.
4. vanRossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterol 2008;135:82-90. (Pubitemid 351899018)
5. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10.
6. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33.
7. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomised controlled trialdSCORE. J Natl Cancer Inst 2011;103:1310-22.
8. Pignone M, Bucholtz D, Russel H. Patient preferences for colorectal cancer screening. J Gen Intern Med 1999;14:432-7. (Pubitemid 29344619)
9. Ling BS, Moskowitz MA, Wachs D, et al. Attitudes toward colorectal cancer screening tests. J Gen Intern Med 2001;16:822-30.
10. Frew EJ, Wolstenholme JL, Whynes DK. Eliciting relative preferences for two methods of colorectal cancer screening. Eur J Cancer Care 2005;14:124-31. (Pubitemid 40655728)
11. Subranmanian S, Bobashev G, Morris RJ. Modelling cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. Cancer Epidemiol Biomarkers Prev 2009;18:1971-8.
12. Wolf RL, Basch CE, Brouse CH, et al. Patient preferences and adherence to colorectal cancer screening in an urban population. Am J Public Health 2006;96:809-11.
13. Imaeda A, Bender D, Fraenkel L. What is most important to patients when deciding about colorectal screening? J Gen Intern Med 2010;25:688-93.
14. Senore C, Armaroli P, Silvani M, et al. Comparing different strategies for colorectal cancer screening in Italy: predictors of patients' participation. Am J Gastroenterol 2010;105:188-98.
15. Paimela H, Malila N, Palva T, et al. Early detection of colorectal cancer with faecal occult blood test screening. Br J Surg 2010;97:1567-71.
16. Steele RJ, Kostourou I, McClements P, et al. Effect of gender, age and deprivation on key performance indicators in a FOBT-based colorectal screening programme. J Med Screen 2010;17:68-74.
17. Zorzi M, Baracco S, Fedato C, et al. Screening for colorectal cancer in Italy: 2008 survey. Epidemiol Prev 2010;34(5-6 Suppl 4):53-72.
18. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-8.
19. Segnan N, Senore C, Andreoni B, et al. SCOR-2 Working Group-Italy. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005;97:347-57. (Pubitemid 40425953)
20. The Multicentre Australian Colorectal-neoplasia Screening (MACS) Group. A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Med J Aust 2006;184:546-50.
21. Jass JR, Sobin LH. Histological Typing of Intestinal Tumors. 2nd edn. New York, Berlin: Springer-Verlag, 1989.
22. Fleiss JL. Statistical Methods for Rates and Proportions. NewYork, NY: John Wiley & Sons, 1981.
23. Hol L, Kuipers EJ, van Ballegoojien M, et al. Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. Int J Cancer 2012;130:2096-102.
24. Schwartz LM, Woloshin S, Black WC, et al. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997;127:966-72. (Pubitemid 27516607)
25. Coulter A. Evidence based patient information is important, so there needs to be a national strategy to ensure it. BMJ 1998;317:225-6.
26. Coulter A, Entwhistle V, Gilbert D. Sharing decision with patients: is the information good enough? BMJ 1999;318:318-22. (Pubitemid 29195144)
27. Austoker J. Gaining informed consent for screening. BMJ 1999;319:722-3. (Pubitemid 29431522)
28. Hoffman RM, Lewis CL, Pignone MP, et al. Decision-making processfor breast, colorectal and prostate cancer screening: the DECISIONS survey. Med Decis Making 2010;30(Suppl 5):53S-64S.
29. Grazzini G, Visioli CB, Zorzi M, et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009;100:259-65.
30. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009;101:1412-22.
31. Zorzi M, Fedato C, Naldoni C, et al. Screening for colorectal cancer in Italy: 2007 survey. Epidemiol Prev 2009;33(Suppl 2):57-74.
32. Segnan N, Senore C, Andreoni B, et al. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology 2007;132:2304-12. (Pubitemid 46900821)